RBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has reiterated an Outperform rating on Arrowhead Pharma (NASDAQ:ARWR) and maintained a $50 price target on the stock.
November 30, 2023 | 2:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Luca Issi reaffirmed an Outperform rating on Arrowhead Pharma and kept the price target at $50.
The reiteration of an Outperform rating by a prominent analyst like Luca Issi from RBC Capital is a positive signal for investors, suggesting confidence in the company's future performance. Maintaining a $50 price target indicates a belief that the stock has the potential to reach or exceed this value in the short term, which could influence investor sentiment and drive the stock price upward.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100